

### Unaudited Interim Condensed Consolidated Financial Statements of

## MOUNTAIN VALLEY MD HOLDINGS INC.

For the three months period ended June 30, 2023 and 2022

(Expressed in thousands of Canadian Dollars)

Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of Canadian Dollars)

	Note	June 30, 2023	March 31, 2023
		\$	\$
Current Assets			
Cash and cash equivalents		8,621	9,714
HST recoverable	_	45	95
Purchase consideration receivable	3	74	74
Prepaids, deposits and other	4	940	978
Right of use asset		-	7
		9,680	10,868
Long-term Assets			
Intangible assets	5	4,104	4,185
Equity investments	6	1,545	1,545
Capital assets	7	650	171
		6,299	5,901
		15,979	16,769
Accounts payable and accrued liabilities Deferred revenue Corporate taxes payable Lease liability		176 140 109	336 140 109 6
		425	591
Shareholders' Equity			
Share capital	8	52,203	52,203
Contributed surplus		5,013	4,942
Warrants		3,152	3,152
Deficit		(44,814)	(44,119)
		15,554	16,178
		15,979	16,769
Approved on behalf of the Board:			
s/ "Dennis Hancock"	/s/ "Ke	evin Puloski"	

Interim Condensed Consolidated Statements of Loss and Comprehensive Loss (Expressed in thousands of Canadian Dollars, except for per share amounts)

	Note	Three months ended, June 30, 2023	Three months ended, June 30, 2022
		\$	\$
Expenses			
General and administrative	9	533	605
Research and development		37	245
Stock based compensation	9	71	174
Amortization of intangible assets	5	87	87
Depreciation of capital assets and right-of use			
assets	7	18	24
Net loss before other items		746	1 135
		/40	1,135
Other items			
Fair value loss on equity investments		-	741
Interest income and other		(51)	(23)
Interest earned on note receivable		-	(1)
		(51)	717
Net loss		695	1,852
Basic and diluted loss per share		(0.00)	(0.01)
Weighted average number of shares outstanding		329,653,424	329,647,895

Interim Condensed Consolidated Statements of Changes in Equity (Expressed in thousands of Canadian Dollars, except for per share amounts)

	Class B	Class B						
	Non-voting	Non-voting	Common Shares	Common Shares	Contributed		Т	otal Shareholders'
	Number of Shares	Share Capital	Number of shares	Share capital	surplus	Warrants	Deficit	Equity
		\$		\$	\$	\$	\$	\$
Balance at March 31, 2022	50,056,229	2,399	329,581,549	52,174	4,597	3,152	(37,474)	24,848
Issuance of stock options	-	-	-	-	174	-	-	174
Shares issued for services	-	-	71,875	29	-	-	-	29
Net loss	-	-	-	-	-	-	(1,852)	(1,852)
Balance at June 30, 2022	50,056,229	2,399	329,653,424	52,203	4,771	3,152	(39,326)	23,199
Balance at March 31, 2023	-	-	329,653,424	52,203	4,942	3,152	(44,119)	16,178
Stock based compensation	-	-	-	-	71	-	-	71
Net loss	-	-	-	-	-	-	(695)	(695)
Balance at June 30, 2023	-	-	329,653,424	52,203	5,013	3,152	(44,814)	15,554

Interim Condensed Consolidated Statements of Cash flows

(Expressed in thousands of Canadian Dollars)

	Note	Three months ended June 30, 2023	Three months ended June 30, 2022
		\$	\$
OPERATING ACTIVITIES			
Net loss		(695)	(1,852)
Adjustments for:			
Common shares issued for consulting services		-	29
Fair value loss on equity investments		-	741
Stock based compensation		71	174
Amortization of intangible assets	5	87	87
Depreciation of capital assets and right-of use assets	7	18	24
Interest earned on convertible note		-	(1)
		(519)	(798)
Changes in non-cash operating working capital			
HST receivable		50	24
Prepaid expenses and deposits		38	55
Accounts payable		(166)	34
Net cash used in operating activities:		(597)	(685)
INVESTING ACTIVITIES			
Purchase of equipment	7	(490)	-
Cash paid to acquire intellectual property	5	(6)	(11)
Net cash used in investing activities:		(496)	(11)
Net change in cash		(1,093)	(696)
Cash and cash equivalents - Beginning		9,714	14,221
Cash and cash equivalents - Ending		8,621	13,525

Notes to the Interim Condensed Consolidated Financial Statements Three months ended June 30, 2023 and June 30, 2022 (Expressed in thousands of Canadian Dollars, except for per share amounts)

### 1. NATURE OF OPERATIONS

Mountain Valley MD Holdings Inc. ("MVMDH" or the "Company"), was incorporated under the provisions of the British Columbia Business Corporations Act on March 8, 2005. The Company is building a world-class health and wellness organization centered around the implementation of its patented Quicksome<sup>™</sup> oral drug formulation and delivery technologies to innovate industry leading products that are sought out globally.

The Company's common shares trade on the Canadian Securities Exchange under the ticker symbol "MVMD."

The address of the Company's registered and records office is 1100 – 1111 Melville Street, Vancouver, BC V6E 3V6 and the principal place of business is 260 Edgeley Boulevard, Unit 4, Vaughan, Ontario, Canada, L4K 3Y4.

#### 2. BASIS OF PRESENTATION

a) Statement of compliance

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting using accounting policies consistent with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").

The Company's board of directors approved the release of these interim condensed consolidated financial statements on August 28, 2023.

b) Basis of measurement

In preparing its consolidated financial statements, the Company makes judgments in applying its accounting policies. The judgments that have the most significant effect on the amounts recognized in the consolidated financial statements are outlined below in section c). In addition, the preparation of consolidated financial statements in conformity with IFRS requires the use of estimates that affect the amounts reported and disclosed in the consolidated financial statements and related notes. These estimates are based on management's best knowledge of the relevant facts and circumstances, having regard to previous experience, but actual results may differ materially from the amounts included in the consolidated financial statements. Information about assumptions and other sources of estimation uncertainty as at March 31, 2023 that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year are outlined below in section c).

c) Areas of judgment and estimation uncertainty

The preparation of the consolidated financial statements in conformity with IFRS requires the use of judgments and/or estimates that affect the amounts reported and disclosed in the consolidated financial statements and related notes. These judgments and estimates are based on management's best knowledge of the relevant facts and circumstances, having regard to previous experience, but actual results may differ materially from the amounts included in the consolidated financial statements.

In preparation of the interim condensed consolidated financial statements, the significant estimates and judgments made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended March 31, 2023.

Notes to the Interim Condensed Consolidated Financial Statements Three months ended June 30, 2023 and June 30, 2022 (Expressed in thousands of Canadian Dollars, except for per share amounts)

### 3. PURCHASE CONSIDERATION RECEIVABLE

On May 31, 2022, the Company signed a share purchase agreement to dispose of its shareholdings in its investment in associate, Sativa Nativa SAS for \$426. The Company received \$352 and the final payment of \$74 remains outstanding.

### 4. PREPAID EXPENSES AND DEPOSITS

	June 30, 2023	March 31, 2023
	\$	\$
Prepaid	105	143
Inventory deposit	817	817
Lease deposits	18	18
	940	978

### 5. INTANGIBLE ASSETS

On December 20, 2019, Mountain Valley MD Inc. entered into an intellectual property asset purchase agreement with a private Delaware corporation in the business of developing, manufacturing and licensing desiccated liposomes. The Company acquired a portfolio of patents, and trademarks. Management determined all the value is attributable to the patents.

The Company's intellectual property consists of the following:

	\$
Cost	
As at March 31, 2023	5,267
Additions	6
As at June 30, 2023	5,273
Accumulated amortization	
As at March 31, 2023	1,082
Depreciation expense	87
As at June 30, 2023	1,169
Carrying amounts:	
As at March 31, 2023	4,185
As at June 30, 2023	4,104

- a) The Company recorded additions of \$6 during the three-month period ended June 30, 2023, related to direct costs to acquire new patents.
- b) The Company recorded \$87 of depreciation during the three-month period ended June 30, 2023 based on the estimated useful life of the portfolio of patents.

No impairment indicators were identified by management as at June 30, 2023

Notes to the Interim Condensed Consolidated Financial Statements Three months ended June 30, 2023 and June 30, 2022 (Expressed in thousands of Canadian Dollars, except for per share amounts)

#### 6. EQUITY INVESTMENTS

The following summarizes the Company's investments at June 30, 2023:

	March 31, 2023	Additions	Disposals	Change in fair value	June 30, 2023
	\$	\$	\$	\$	\$
Sixth Wave Innovations Inc. (a)	5	-	-	-	5
Circadian Wellness Corp. (b)	1,222	-	-	-	1,222
Agrarius Corp. (c)	203	-	-	-	203
Agroresults Inc. (d)	115	-	-	-	115
	1,545	-	-	-	1,545

#### a) Sixth Wave Innovations Inc.

As at June 30, 2023, management valued the investment at \$5 (March 31, 2023: \$5) based on Level 1 input under the IFRS 13 fair value hierarchy using the trading price of Sixth Wave Innovations Inc. as at June 30, 2023.

#### b) Circadian Wellness Corp.

The Company owns 1,222,222 shares (post 3:1 share split on May 27, 2021) of Circadian Wellness Corp. a private Ontario corporation focusing on mushroom farming, extraction, clinical research and development, and end-user consumer health and wellness products and retreats.

As at June 30, 2023, management fair valued Circadian Wellness Corp. using Level 3 inputs under the IFRS 13 fair value hierarchy. The fair value was based on the most recent private financing done by Circadian Wellness Corp. Management has determined no subsequent change in fair value.

#### c) Agrarius Corp.

On October 4, 2022, the Company made an equity investment of \$203 in Agrarius Corp, a private US corporation.

As at June 30, 2023, management fair valued Agrarius Corp. using Level 3 inputs under the IFRS 13 fair value hierarchy. The fair value was based on the purchase price of the shares in Agrarius Corp., and management has determined no subsequent change in fair value.

#### d) Agroresults Inc.

On November 4, 2022, the Company converted the note receivable of \$115 into 1072 common shares of Agroresults Inc. a private Canadian company, and majority owner of Agrarius Corp. This represents 1% ownership of Agroresults Inc.

As at June 30, 2023, management fair valued Agroresults Inc. using Level 3 inputs under the IFRS 13 fair value hierarchy. The fair value was based on the conversion price of the shares. Management has determined no subsequent change in fair value.

Notes to the Interim Condensed Consolidated Financial Statements Three months ended June 30, 2023 and June 30, 2022 (Expressed in thousands of Canadian Dollars, except for per share amounts)

## 7. CAPITAL ASSETS

	Office and Lab	Leasehold	
	Equipment	Improvements	Total
	\$	\$	\$
Cost			
At March 31, 2023	221	109	330
Additions	490	-	490
At June 30, 2023	711	109	820
Accumulated amortization			
At March 31, 2023	93	66	159
Depreciation expense	6	5	11
At June 30, 2023	99	71	170
Carrying amounts:			
At March 31, 2023	128	43	171
At June 30, 2023	612	38	650

#### 8. SHARE CAPITAL

a) Share Capital

Authorized

The Company has Unlimited Common Shares without par value.

#### Issued and outstanding

The Company has issued share capital of 329,653,424 Common Shares.

#### Share issuances during the three months ended June 30, 2022

The Company issued 71,875 shares for consulting services at a deemed price of \$0.40 for a value of \$29.

b) Stock Options

The Company has a share option plan, under which the Board of Directors is authorized to grant options to employees, directors, officers and consultants, enabling them to acquire up to 10% of the issued and outstanding share capital of the Company. The exercise price of each option is based on the market price of the Company's share as calculated on the date of grant or the date preceding the date of grant, whichever is higher. The options can be granted for a maximum term of ten years, as determined by the Company's Board of Directors. Options granted to investor relations consultants are subject to vesting provisions, with no more than <sup>1</sup>/<sub>4</sub> vesting during any three-month period. Vesting provisions for other options are determined by the Company's Board of Directors.

Notes to the Interim Condensed Consolidated Financial Statements Three months ended June 30, 2023 and June 30, 2022 (Expressed in thousands of Canadian Dollars, except for per share amounts)

### .... Note 8. SHARE CAPITAL (Continued)

The continuity of the Company's stock options is as follows:

	Outstanding Options	Weighted Average Exercise Price
		\$
Balance at March 31, 2021	12,798,500	0.49
Issued	7,295,000	0.29
Forfeited	(200,000)	1.45
Cancelled	(2,590,000)	2.04
Excercised	(600,000)	0.07
Balance at March 31, 2022	16,703,500	0.16
Issued	3,020,000	0.05
Forfeited	(80,000)	0.14
Balance at March 31, 2023 and June 30, 2023	19,643,500	0.15

The following table summarizes the stock options outstanding at June 30, 2023:

Expiry Date	Number	Weighted Average Exercise Price	Options exercisable
		\$	
March 13, 2025	3,785,000	0.07	3,785,000
May 1, 2025	250,000	0.075	250,000
May 3, 2025	4,288,500	0.05	4,288,500
December 1, 2025	135,000	0.095	135,000
December 14, 2025	1,000,000	0.29	1,000,000
July 14, 2026	3,640,000	0.27	3,640,000
August 1, 2026	1,000,000	0.365	1,000,000
January 25, 2027	2,525,000	0.22	2,525,000
April 7, 2027	50,000	0.13	50,000
March 6, 2028	2,970,000	0.05	594,000
	19,643,500	0.15	17,267,500

#### c) Warrants

The continuity of the Company's share purchase warrants is as follows:

		Weighted	Weighted
		Average	Average
	Outstanding	Remaining	Exercise
	Warrants	Life (Years)	Price
			\$
March 31, 2022	14,127,763		0.44
Expired	(13,252,763)		0.37
Balance at March 31, 2023 and June 30, 2023	875,000	0.28	0.48

Notes to the Interim Condensed Consolidated Financial Statements Three months ended June 30, 2023 and June 30, 2022 (Expressed in thousands of Canadian Dollars, except for per share amounts)

#### .... Note 8. SHARE CAPITAL (Continued)

The following table summarizes the share purchase warrants outstanding at June 30, 2023:

		Weighted
		Average
		Exercise
Expiry Date	Number	Price
		\$
July 11, 2023	875,000	0.48
	875,000	0.48

#### 9. RELATED PARTY TRANSACTIONS

Key management consists of personnel having the authority and responsibility for planning, directing and controlling the activities of the Company, which are the directors and executive officers of the Company:

Three months ended June 30,	2023	2022
	\$	\$
	22	100
Consulting fees	96	180
Director fees	24	-
Stock based compensation	42	104
	162	284

#### 10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company's financial instruments include cash and cash equivalents, purchase consideration receivable, accounts payable and accrued liabilities. The carrying amounts of these financial instruments are a reasonable estimate of their fair values based on their current nature and current market rates for similar financial instruments.

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of inputs used to estimate the fair values. The three levels of the fair value hierarchy are

Level 1 – Unadjusted quoted prices in active markets for identical assets and liabilities; Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and Level 3 – Inputs that are not based on observable market data.

As at June 30, 2023, the Company did not have any financial assets and liabilities which are measured at fair value, other than equity investments. There were no transfers between Level 1, 2 or 3 during the three months ended June 30, 2023.

#### a) Credit risk

:

Credit risk is the risk that the financial benefits of contracts with a specific counterparty will be lost if a counterparty defaults on its obligations under the contract. Credit risk arises from cash and cash equivalents. The amount of credit risk related to cash and cash equivalents is considered insignificant as the Company's funds are held with a large Canadian bank.

The credit risk for the cash and cash equivalent is monitored quarterly, and any change is reflected as an adjustment through expected credit loss.

#### .... Note 10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Continued)

b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure. The Company monitors and reviews current and future cash requirements and matches the maturity profile of financial assets and liabilities.

As at June 30, 2023, the Company's financial liabilities have contractual maturities as summarized below:

	0-12 months	1-2 years	2-3 years
	\$	\$	\$
Accounts payable and accrued liabilities	176	-	-
Total	176	-	-

#### c) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices and is comprised of currency risk, interest rate risk, and other price risk.

#### Sensitivity analysis

The Company has completed a sensitivity analysis to estimate the impact on comprehensive earnings which a change in the equity investments would have on the Company during the three months ended June 30, 2023. As a result, a 10% change in the equity investments will translate to a \$32 (three months ended June 30, 2022, \$429) gain or loss from equity investments.

#### 11. SEGMENT INFORMATION

Management has determined that the Company has two reportable operating segments, research and development of its delivery, solubility, and adjuvant technologies and agriculture.

For the three months ended June 30, 2023, total operating expenses related to agriculture is \$115 (three months ended June 30, 2022: \$nil). Determination of the operating segments was based on the level of financial reporting to the Company's chief decision makers.

### 12. CAPITAL MANAGEMENT

The Company manages its cash, common shares, warrants and share purchase options as capital. The Company's objectives when managing capital are to safeguard its ability to continue as a going concern and to maintain a flexible capital structure which optimizes the costs of capital at an acceptable risk.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, acquire or dispose of assets or adjust the amount of cash held.